参麦注射液临床应用的安全性评估及其影响因素分析  

Safety Assessment and Influential Factors Analysis of Shenmai Injection in the Clinic

作　　者：刘存富[1] 颜廷华[2] 

机构地区：[1]南通大学附属建湖医院药剂科,江苏建湖224700 [2]南通大学附属建湖医院肿瘤科,江苏建湖224700

出　　处：《中国药房》2014年第44期4195-4197,共3页China Pharmacy

摘　　要：目的:评估参麦注射液临床应用的安全性并探讨其影响因素。方法:通过医院信息系统(HIS)数据库,收集全国30家三级甲等医疗卫生机构使用参麦注射液的数据,就收集到的患者资料及不良反应(ADR)相关信息进行分析。结果:共纳入18 532例患者,参麦注射液多应用于60岁以上患者,原患疾病主要为肿瘤、冠心病、慢性肺心病等。其中,有15例患者发生ADR,ADR发生率为0.81‰,主要表现为皮疹、心悸、胸闷等,均为罕见发生,高龄和超适应证用药是ADR发生的危险因素。结论:参麦注射液临床应用广泛,安全性较好,但临床仍需重视按照说明书和适应证用药,对过敏体质者需谨慎用药,以减少ADR的发生。OBJECTIVE：To evaluate the clinical safety of Shenmai injection and analyze its influential factors. METHODS：The data of clinical application of Shenmai injection were collected from 30 third-grade class A hospitals by using HIS database.The information of patients,the incidence and influential factors of ADR were analyzed statistically. RESULTS：Most of people who used Shenmai injection were over 60 years,and common indications were cancer,coronary heart disease and chronic pulmonary heart disease. The incidence of ADR was 0.81‰;the main manifestations of ADR were rash,palpitations,chest tightness,palpitation,etc. Elderly and ultra-indication use were risk factors for ADR. CONCLUSIONS：Shenmai injection is widely used in the clinic and shows good safety. Great importance should be attached to drug use according to package inserts and indication,and allergic people should use it carefully to reduce the incidence of ADR.

关 键 词：参麦注射液 安全性 影响因素 不良反应 

分 类 号：R969[医药卫生—药理学]